(Total Views: 431)
Posted On: 09/30/2025 12:02:29 PM
Post# of 157591
Yes, there are a lot of positives in this letter and hopefully it will allay a lot of bad feelings among shareholders. HOWEVER, this section stopped me in my tracks:
"leronlimab continues to advance in the treatment of metastatic Colorectal Cancer (mCRC). Enrollment in our Phase II study is underway with five sites initiated and several more onboarding in the next several weeks. The enrollment of our fifth patient in the trial will trigger the Data Safety Monitoring Board (DSMB) safety review, which could then open study randomization to include the 700 mg dose."
I can't remember how many months ago CYDY started enrolling patients in this trial, and they only have 4 enrolled so far??? That is incredibly disappointing to me. So much depends on this trial proving MOA of increasing PD-L1 and the "light at the end of the tunnel" seems to keep receding. Sadly, Ganesha
"leronlimab continues to advance in the treatment of metastatic Colorectal Cancer (mCRC). Enrollment in our Phase II study is underway with five sites initiated and several more onboarding in the next several weeks. The enrollment of our fifth patient in the trial will trigger the Data Safety Monitoring Board (DSMB) safety review, which could then open study randomization to include the 700 mg dose."
I can't remember how many months ago CYDY started enrolling patients in this trial, and they only have 4 enrolled so far??? That is incredibly disappointing to me. So much depends on this trial proving MOA of increasing PD-L1 and the "light at the end of the tunnel" seems to keep receding. Sadly, Ganesha
(13)
(0)
